{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-246896","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2021-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.908292+00:00","generated_at":"2026-06-29T09:58:37.472045+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cogent Biosciences Q2 net loss $16.5M; cash $218.1M; initiates Phase 2 APEX trial for bezuclastinib in AdvSM","bullets":["Net loss of $16.5M for Q2 2021 vs $7.4M in Q2 2020; R&D spend $12.4M, G&A $4.9M.","Cash and equivalents $218.1M as of June 30, 2021; expects runway into 2024.","Phase 2 APEX open-label study of bezuclastinib in Advanced Systemic Mastocytosis initiated; preliminary data expected 1H 2022.","SUMMIT Phase 2 study in NonAdvSM on track to start 2H 2021 after positive FDA interactions.","FDA granted orphan drug designation for bezuclastinib in GIST; new study with sunitinib planned 2H 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-246896","json":"https://secwatch.observer/filing/0001193125-21-246896.json","markdown":"https://secwatch.observer/filing/0001193125-21-246896.md","text":"https://secwatch.observer/filing/0001193125-21-246896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312521246896/0001193125-21-246896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312521246896/d204129d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T09:58:37.472045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}